Novozymes Biopharma has collaborated with the University of Oslo to develop enhanced albumin fusion technology that tailors and controls the pharmacokinetics of target proteins and peptides.
Built on Novozymes' original Albufuse platform, the Albufuse Flex technology has been designed to enable users to adapt and control the pharmacokinetics of their target protein or peptide with retained efficacy, ensuring flexibility and optimal use.
It has been shown that by manipulating the interaction of albumin and IgGs with FcRn, it is possible to tailor their half-life.
The Albufuse Flex technology has been developed to facilitate manipulation based on this FcRn-albumin interaction, enabling a tunable half-life that offers control and flexibility and that, potentially, may improve overall treatment efficacy and patient compliance.
In addition to protein- or peptide-based drugs, the enhanced technology also provides a delivery vehicle for small molecules, providing a broad scope of usability.
